ESMO WCGIC 2020 | Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions

Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, describes a retrospective analysis on the efficacy of second-line chemotherapy in patients enrolled in the PROOF study (NCT03773302) with advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusions. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).